RT Journal Article SR Electronic T1 Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.07.14.20151159 DO 10.1101/2020.07.14.20151159 A1 Kai Wang A1 Quan-Xin Long A1 Hai-Jun Deng A1 Jie Hu A1 Qing-Zhu Gao A1 Gui-Ji Zhang A1 Chang-Long He A1 Lu-Yi Huang A1 Jie-Li Hu A1 Juan Chen A1 Ni Tang A1 Ai-Long Huang YR 2020 UL http://medrxiv.org/content/early/2020/07/17/2020.07.14.20151159.abstract AB Background Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of SARS-CoV-2-specific neutralizing antibodies (NAbs) in COVID-19 patients.Methods Blood samples (n=173) were collected from 30 COVID-19 patients over a 3-month period after symptom onset and analyzed for SARS-CoV-2-specific NAbs, using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines.Results SARS-CoV-2-specific NAb titers were low for the first 7-10 d after symtom onset and increased after 2-3 weeks. The median peak time for NAbs was 33 d (IQR 24-59 d) after symptom onset. NAb titers in 93.3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34.8% (IQR 19.6-42.4%). NAb titers increased over time in parallel with the rise in IgG antibody levels, correlating well at week 3 (r = 0.41, p < 0.05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including SCF, TRAIL, and M-CSF.Conclusions These data provide useful information regarding dynamic changes in NAbs in COVID-19 patients during the acute and convalescent phases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Emergency Project from the Science & Technology Commission of Chongqing (cstc2020jscx-fyzx0053), the Emergency Project for Novel Coronavirus Pneumonia from the Chongqing Medical University (CQMUNCP0302, CQMUNCP0304), the Leading Talent Program of CQ CSTC (CSTCCXLJRC201719), and a Major National Science & Technology Program grant (2017ZX10202203) from the Science & Technology Commission of China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Commission of Chongqing Medical University (ref. no. 2020003). Written informed consent was waived by the Ethics Commission of the designated hospital for emerging infectious diseases.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this study are available from the authors upon request.